{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:19:57Z","timestamp":1788358797569,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Therapies with robust visual outcomes and reduced patient and healthcare system treatment burden are needed amidst the rising incidence of neovascular age-related macular degeneration (nAMD). Aflibercept 8\u2009mg is an additional treatment option with demonstrated potential for extended dosing intervals of up to 24 weeks. The objective of this publication is to introduce a clinical care pathway, developed by expert consensus of experienced UK clinicians, to support best practice with aflibercept 8\u2009mg in nAMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured, face-to-face roundtable meeting of 13 UK retina specialists was held on 8 October 2024, organised and funded by Bayer. The expert panel reached consensus following review of key clinical trial data and consideration of current NHS clinical practice to provide guidance on the use of intravitreal aflibercept 8\u2009mg in nAMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panel provided recommendations for an aflibercept 8\u2009mg treat-and-extend pathway for both treatment-na\u00efve and previously treated patients with nAMD. Criteria were developed to guide dosing interval extension, reduction or maintenance based on visual acuity and optical coherence tomography imaging. More detailed guidance includes considerations for switching treatments to or from aflibercept 8\u2009mg, monitoring, and discontinuing treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aflibercept 8\u2009mg may offer opportunities for longer treatment intervals and reduced patient and clinic burden compared with first-generation agents. The proposed treatment pathway is practical and accounts for variability in healthcare structures and capacity pressures, providing clinicians with flexibility in implementing these recommendations while addressing patient needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04180-8","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:49:16Z","timestamp":1768546156000},"page":"959-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Aflibercept 8\u2009mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0213-6253","authenticated-orcid":false,"given":"Richard","family":"Gale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9878-2447","authenticated-orcid":false,"given":"Mahmoud Husseiny","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramandeep","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-8162","authenticated-orcid":false,"given":"Faruque","family":"Ghanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Kotagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirodhini","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-0381","authenticated-orcid":false,"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Napier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeen","family":"Ismat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"4180_CR1","unstructured":"The Royal College of Ophthalmologists. National Ophthalmology Database Audit | The second report of age-related macular degeneration audit (AMD): patients starting treatment for neovascular AMD in the 2021 NHS year (01 April 2021 to 31 March 2022). March 2024; London, UK: The Royal College of Ophthalmologists. Accessed 6 February 2025. https:\/\/nodaudit.org.uk\/sites\/default\/files\/2024-05\/NOD%20Audit%20AMD%20Full%20Annual%20Report%202024_0.pdf."},{"key":"4180_CR2","unstructured":"The Royal College of Ophthalmologists. Census Report | Facing workforce shortages and backlogs in the aftermath of COVID-19: the 2022 census of the ophthalmology consultant, trainee and SAS workforce. March 2023; London, UK: The Royal College of Ophthalmologists. Accessed 6 February 2025. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2023\/03\/2022-Ophthalmology-census-Facing-workforce-shortages-and-backlogs-in-the-aftermath-of-COVID-19.pdf."},{"key":"4180_CR3","unstructured":"The Royal College of Ophthalmologists. Commissioning Guidance | Age related macular degeneration services: recommendations. May 2024; London, UK: The Royal College of Ophthalmologists. Accessed 6 February 2025. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/08\/AMD-Services-Commissioning-Guidance-Recommendtions.pdf."},{"key":"4180_CR4","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41433-021-01646-3","volume":"36","author":"R Chopra","year":"2022","unstructured":"Chopra R, Preston GC, Keenan TDL, Mulholland P, Patel PJ, Balaskas K, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye. 2022;36:1373\u201378.","journal-title":"Eye"},{"key":"4180_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/03007995.2024.2362278","volume":"40","author":"S Sivaprasad","year":"2024","unstructured":"Sivaprasad S, Bailey C, Downey L, Gilbert R, Gale R, Kotagiri A, et al. Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Curr Med Res Opin. 2024;40:1221\u201333.","journal-title":"Curr Med Res Opin"},{"key":"4180_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","volume":"33","author":"RP Gale","year":"2019","unstructured":"Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019;33:1\u201321.","journal-title":"Eye"},{"key":"4180_CR7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"4180_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.08.022","author":"JF Korobelnik","year":"2025","unstructured":"Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: 96-week results from the randomized phase 3 PULSAR trial. Ophthalmology. 2025. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022.","journal-title":"Ophthalmology"},{"key":"4180_CR9","unstructured":"Bayer plc. Eylea 114.3 mg\/ml solution for injection in pre-filled syringe \u2013 summary of product characteristics; updated 9 September 2024. Bayer plc: Reading, UK."},{"key":"4180_CR10","unstructured":"Bayer plc. Eylea 40 mg\/ml solution for injection in a vial \u2013 summary of product characteristics; updated 11 September 2023. Bayer plc: Reading, UK."},{"key":"4180_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2023","unstructured":"Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye. 2023;37:6\u201316.","journal-title":"Eye"},{"key":"4180_CR12","unstructured":"NHS England. Commissioning guidance: medical retinal treatment pathway in wet age-related macular degeneration 2025. https:\/\/uk-oa.co.uk\/wp-content\/uploads\/2025\/08\/Commissioning-Guidance-Medical-Retinal-Treatment-Pathway-in-Wet-Age-related-Macular-Degenerati-1.pdf."},{"key":"4180_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR \u2013 a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"4180_CR14","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration \u2013 the ARIES study: a randomized clinical trial. Retina. 2021;41:1911\u201320.","journal-title":"Retina"},{"key":"4180_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"4180_CR16","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41433-022-02264-3","volume":"37","author":"C Bailey","year":"2023","unstructured":"Bailey C, Cackett P, Kotagiri A, Mahmood S, Minos E, Narendran N, et al. Practical implementation of a q4\u2013q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: updated guidance from a UK expert panel. Eye. 2023;37:1916\u201321.","journal-title":"Eye"},{"key":"4180_CR17","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","volume":"34","author":"AH Ross","year":"2020","unstructured":"Ross AH, Downey L, Devonport H, Gale RP, Kotagiri A, Mahmood S, et al. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye. 2020;34:1825\u201334.","journal-title":"Eye"},{"key":"4180_CR18","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41433-024-03223-w","volume":"38","author":"L Downey","year":"2024","unstructured":"Downey L, Sivaprasad S, Chhabra R, Bailey C, Chakrabarti S, Elsherbiny S, et al. Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists. Eye. 2024;38:3077\u201386.","journal-title":"Eye"},{"key":"4180_CR19","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.2147\/OPTH.S481772","volume":"18","author":"N Narendran","year":"2024","unstructured":"Narendran N, Bailey C, Downey L, Gale R, Kotagiri A, Pearce I, et al. Expert panel consensus for optimizing outcomes in neovascular age-related macular degeneration in the context of suboptimal response to a biosimilar: the role of aflibercept. Clin Ophthalmol. 2024;18:3133\u201342.","journal-title":"Clin Ophthalmol"},{"key":"4180_CR20","unstructured":"The Royal College of Ophthalmologists. Intravitreal injection therapy. Accessed 6 February 2025. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2022\/02\/Intravitreal-Injection-Therapy-August-2018-1.pdf."},{"key":"4180_CR21","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s40123-024-01002-0","volume":"13","author":"J Uzzan","year":"2024","unstructured":"Uzzan J, Mapani A, Cox O, Bagijn M, Saffar I. Clinical outcomes and experiences with prefilled syringes versus vials for intravitreal administration of anti-VEGF treatments: a systematic review. Ophthalmol Ther. 2024;13:2445\u201365.","journal-title":"Ophthalmol Ther"},{"key":"4180_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2147\/OPTH.S393519","volume":"17","author":"U Schmidt-Ott","year":"2023","unstructured":"Schmidt-Ott U, Fitzpatrick S, Hasanbasic Z, Leal S, Morgan-Warren P, Zhang X, et al. Reported rates of intraocular inflammation with intravitreal aflibercept administered via pre-filled syringe or from vials in clinical practice between 2012 and 2022. Clin Ophthalmol. 2023;17:385\u201390.","journal-title":"Clin Ophthalmol"},{"key":"4180_CR23","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.3390\/jcm14144821","volume":"14","author":"M Yamamoto","year":"2025","unstructured":"Yamamoto M, Hirayama K, Kyo A, Kinari G, Kojima Y, Kohno T, et al. Immediate and short-term intraocular pressure changes following intravitreal injection and associated factors. J Clin Med. 2025;14:4821.","journal-title":"J Clin Med"},{"key":"4180_CR24","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41433-022-02077-4","volume":"37","author":"U Schmidt-Erfurth","year":"2023","unstructured":"Schmidt-Erfurth U, Mulyukov Z, Gerendas BS, Reiter GS, Lorand D, Weissgerber G, et al. Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis. Eye. 2023;37:1160\u201369.","journal-title":"Eye"},{"key":"4180_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41433-024-03399-1","volume":"39","author":"S Yu","year":"2025","unstructured":"Yu S, Jones IL, Maunz A, Bachmeier I, Albrecht T, Ebneter A, et al. Artificial intelligence-based analysis of retinal fluid volume dynamics in neovascular age-related macular degeneration and association with vision and atrophy. Eye. 2025;39:154\u201361.","journal-title":"Eye"},{"key":"4180_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1204026","volume":"10","author":"SC Cho","year":"2023","unstructured":"Cho SC, Park KH, Park SJ, Joo K, Woo SJ. Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5. Front Med. 2023;10:1204026.","journal-title":"Front Med"},{"key":"4180_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19062-2","volume":"12","author":"Y Hirata","year":"2022","unstructured":"Hirata Y, Oishi A, Maekawa Y, Tsuiki E, Machida A, Kurihara J, et al. Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen. Sci Rep. 2022;12:14768.","journal-title":"Sci Rep"},{"key":"4180_CR28","unstructured":"General Medical Council. Decision making and consent. Last update: 13 December 2024. https:\/\/www.gmc-uk.org\/professional-standards\/the-professional-standards\/decision-making-and-consent."},{"key":"4180_CR29","unstructured":"National Institute for Health and Care Excellence (NICE). NG82: Age-related macular degeneration. https:\/\/www.nice.org.uk\/guidance\/ng82."},{"key":"4180_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.oret.2023.12.012","volume":"8","author":"RP Gale","year":"2024","unstructured":"Gale RP, Airody A, Sivaprasad S, Hanson RLW, Allgar V, McKibbin M, et al. Improved structure and function in early-detected second-eye neovascular age-related macular degeneration: FASBAT\/early detection of neovascular age-related macular degeneration report 1. Ophthalmol Retina. 2024;8:545\u201352.","journal-title":"Ophthalmol Retina"},{"key":"4180_CR31","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/life15060903","volume":"15","author":"M Musadiq","year":"2025","unstructured":"Musadiq M, Musadiq M, Latif F, Ng B, Azzopardi M, Gilead N, et al. Early real-world outcomes of switching to 8 mg aflibercept for neovascular age-related macular degeneration in the United Kingdom. Life. 2025;15:903.","journal-title":"Life"},{"key":"4180_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/ph18030438","volume":"18","author":"S Hosoda","year":"2025","unstructured":"Hosoda S, Sakurada Y, Fukuda Y, Kotoda Y, Kikushima W, Kashiwagi K. Short-term outcomes of three consecutive monthly loading administrations of aflibercept 8 mg for treatment-naive exudative age-related macular degeneration. Pharmaceuticals. 2025;18:438.","journal-title":"Pharmaceuticals"},{"key":"4180_CR33","doi-asserted-by":"publisher","unstructured":"Abu Ishkheidem I, Inci E, Breimer M, Silfversward ST, Zetterberg M, Gronlund MA. Real-world outcomes of aflibercept 8\u2009mg in patients previously treated for neovascular age-related macular degeneration. Acta Ophthalmol. 2025. https:\/\/doi.org\/10.1111\/aos.17590.","DOI":"10.1111\/aos.17590"},{"key":"4180_CR34","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.3390\/jcm14144900","volume":"14","author":"C Palm","year":"2025","unstructured":"Palm C, Zweifel SA, Gabathuler F, Cozzi M, Fasler K. Efficacy of aflibercept 8 mg in pretreated age-related macular degeneration. J Clin Med. 2025;14:4900.","journal-title":"J Clin Med"},{"key":"4180_CR35","doi-asserted-by":"publisher","first-page":"e002091","DOI":"10.1136\/bmjophth-2024-002091","volume":"10","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025;10:e002091.","journal-title":"BMJ Open Ophthalmol"},{"key":"4180_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3928\/23258160-20241205-01","volume":"56","author":"B Momenaei","year":"2025","unstructured":"Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of intravitreal aflibercept 8 mg in eyes with neovascular age-related macular degeneration previously treated with faricimab. Ophthalmic Surg Lasers Imaging Retina. 2025;56:206\u201311.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4180_CR37","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/09273948.2025.2476061","volume":"33","author":"MH Nowroozzadeh","year":"2025","unstructured":"Nowroozzadeh MH, Hajipourkhorasani M. Increased risk of retinal vasculitis may be associated with aflibercept 8 mg: A pharmacovigilance analysis of the FAERS database. Ocul Immunol Inflamm. 2025;33:1056\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"4180_CR38","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10384-025-01229-9","volume":"69","author":"H Matsumoto","year":"2025","unstructured":"Matsumoto H, Hoshino J, Numaga S, Asatori Y, Akiyama H. Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naive neovascular age-related macular degeneration. Jpn J Ophthalmol. 2025;69:911\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"4180_CR39","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s10384-025-01239-7","volume":"69","author":"X Lu","year":"2025","unstructured":"Lu X, Kataoka K, Kumagai M, Nochi Y, Yamamoto A, Ko R, et al. Comparison of intraocular pressure elevation following intravitreal injection of 70 microl aflibercept 8 mg. Jpn J Ophthalmol. 2025;69:926\u201331.","journal-title":"Jpn J Ophthalmol"},{"key":"4180_CR40","volume":"17","author":"P Gartaganis","year":"2025","unstructured":"Gartaganis P, Khamis N, Hamoud Bedan A, Driouich Z, Ashraf MO, Abucar Osman S, et al. A comparative assessment of intraocular pressure changes after aflibercept 8 mg and faricimab-svoa intravitreal injections in wet age-related macular degeneration. Cureus. 2025;17:e88617.","journal-title":"Cureus"},{"key":"4180_CR41","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41433-022-02153-9","volume":"36","author":"U Chakravarthy","year":"2022","unstructured":"Chakravarthy U, Armendariz BG, Fauser S. 15 years of anti-VEGF treatment for nAMD: success or failure or something in between? Eye. 2022;36:2232\u201333.","journal-title":"Eye"},{"key":"4180_CR42","first-page":"327","volume":"263","author":"SW Quist","year":"2025","unstructured":"Quist SW, Nab H, Postma M, Amarakoon S, van Asten F, Freriks R. A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands. Graefes Arch Clin Exp Ophthalmol. 2025;263:327\u201345.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4180_CR43","unstructured":"NHS England. Operational note: updated commissioning recommendations for medical retinal vascular medicines following the national procurement for ranibizumab biosimilars. Accessed 6 February 2025. https:\/\/www.england.nhs.uk\/long-read\/operational-note-updated-commissioning-recommendations-for-medical-retinal-vascular-medicines-following-the-national-procurement-for-ranibizumab-biosimilars\/."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04180-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:29:19Z","timestamp":1778488159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04180-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4180"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04180-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been made open access retrospectively.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Richard Gale: Travel grants and honoraria from AbbVie, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Ocular Therapeutix and Roche. Mahmoud Husseiny Awad: Travel grants and honoraria from AbbVie, Bayer and Roche. Clare Bailey: Travel grants and honoraria from Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Janssen Pharmaceuticals and Roche. Peter Cackett: Travel grants and honoraria from AbbVie, Apellis, Bayer, Novartis and Roche. Ramandeep Chhabra: Honoraria for advisory boards, travel grants and speaker engagements for educational meetings from Alimera Sciences, Bayer, Novartis and Roche. Louise Downey: Travel grants from Allergan, Bayer, Novartis and Roche; honoraria and research funding from AbbVie, Alimera Sciences, Allergan, Bausch + Lomb, Bayer, Biogen, Novartis and Roche. Faruque Ghanchi: Travel grants and honoraria from AbbVie, Alimera, Bayer, Boehringer Ingelheim, Heidelberg (UK) and Roche. Ajay Kotagiri: Advisory board attendances for AbbVie, Bayer, Novartis and Roche; speaker fees from AbbVie and Bayer; travel grants from AbbVie, Bayer, Novartis and Roche. Nirodhini Narendran: Travel grants and honoraria from Bayer, Novartis and Roche. Ian Pearce: Travel grants and honoraria from Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis and Roche. Tunde Peto: Speaker\u2019s fee and honoraria from AbbVie, Apellis, Bayer, Boehringer Ingelheim, Heidelberg Engineering, Novartis, Optos and Roche; investigator-initiated grant (paid to institution) from Boehringer Ingelheim and Novartis.\n                      Eye\n                      editorial board member. Sobha Sivaprasad: Travel grants and honoraria from AbbVie, Adverum, Alimera Sciences, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, Eyebiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Kriya Therapeutics, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Ripple Therapeutics, Roche, Sanofi and Stealth BioTherapeutics.\n                      Eye\n                      editorial board member. Saad Younis: Travel grants and honoraria from AbbVie, Bayer and Roche. Jackie Napier was an employee of Bayer plc, UK, during the development of the manuscript, but is no longer affiliated with the company. Rose Gilbert and Safeen Ismat: Employees of Bayer plc, UK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}